Dr Iams on the Effect of the FLAURA2 Trial in EGFR-Mutant NSCLC

Wade T. Iams, MD, assistant professor of medicine, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, discusses the impact of the phase 3 FLAURA2 trial (NCT04035486) in patients with EGFR-mutant non–small cell lung cancer (NSCLC) , highlighting the notable improvements in progression-free survival (PFS) that this approach elicits.

Investigators presented updated data from the trial during the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer. Updated data from the study showed that osimertinib (Tagrisso) plus platinum-based chemotherapy and pemetrexed produced a statistically significant and clinically meaningful improvement in PFS when compared withosimertinib monotherapy in patients with advanced, EGFR-mutated disease.

Notably median PFS increased from 16.7 months with osimertinib alone to 25.5 months with the combinationin this patient group, Iams adds. The 12-month PFS rates were 80% with the combination and 66%, with single-agent osimertinib. The 24-month PFS rates were 57% vs 41%, respectively.

Iams emphasizes that this improvement in PFS closely aligns with previous hypotheses regarding the survival data, which solidify the use of osimertinib in the adjuvant setting. Moreover, survival data from FLAURA2 indicate that the addition of platinum-doublet chemotherapy to initial treatment regimens should be the standard approach for patients with metastatic EGFR-mutant NSCLC.

In summary, the data from FLAURA2 further demonstrate the potential benefits associated with the upfront use of combination therapy in metastatic EGFR-mutant NSCLC, Iams concludes.